Leland Stanford Junior University

Ardelyx, Inc.

Immunogenics LLC

Washington University

Alvine Pharmaceuticals, Inc.

Matthew John Siegel

Chaitan Khosla

Michael Robert Leadbetter

Bret Berner

Jeffrey William Jacobs

Dean R Dragoli

Jason Gustaf Lewis

Noah Bell

Kihang Choi

Richard Edward Watts

Tao Chen

Rakesh K Jain

Daniel Meron Pinkas

Jeremy Caldwell

Patricia Finn

Keith M Rich

Christopher Carreras

Michael Thomas Bethune

Irina Dotsenko

Jonathan David Gass

Andrew King

Jiang Xia

Ying He

The invention relates to non-systemic TGR5 agonist useful in the treatment of chemotherapy-induced diarrhea, diabetes, Type II diabetes, gestational diabetes, impaired fasting glucose, impaired glucose tolerance, insulin resistance, hyperglycemia, obesity, metabolic syndrome, ulcerative colitis, Crohn's disease, disorders associated with parenteral nutrition especially during short bowel syndrome, and irritable bowel syndrome (IBS), and other TGR5 associated diseases and disorders, having the Formula: where R, R, R, R, R, X, X, X, X, Q, and n are described herein.

Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists

Oral administration of ALV003 can protect celiac disease patients and patients otherwise suffering from gluten-intolerance from the harmful effects of ingesting food containing gluten.

Methods and pharmaceutical compositions for treating celiac disease and gluten intolerance

The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.

Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders

Pharmaceutical formulations of orally administered proteins can be stabilized from oxidative degradation and inactivation in the stomach and GI tract by the addition of an antioxidant.

Formulation for oral administration of proteins

Transglutaminase inhibitors and methods of use thereof are provided.

Transglutaminase inhibitors and methods of use thereof

A combination enzyme product consisting of a glutamine specific endoprotease and a prolyl endopeptidase is provided. Both enzymes are active and stable in the stomach and can therefore be administered as lyophilized powders or simple capsules/tablets. A ratio of the two enzymes is used to maximize their synergy.

Combination enzyme therapy for digestion of dietary gluten

Detection of toxic gluten oligopeptides refractory to digestion and antibodies and T cells responsive thereto can be used to diagnose Celiac Sprue. Analogs of such oligopeptides are useful in the inhibition of immune responses.

Peptides for diagnostic and therapeutic methods for celiac sprue

Growing community of inventors

Menlo Park, CA, United States of America

Matthew John Siegel